Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
February 09, 2026
February 09, 2026
BOSTON, Massachusetts, Feb. 9 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
*
Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
Dana-Farber Cancer Institute -led research helped drive an FDA label update for axicabtagene ciloleucel (Y . . .
* * *
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
*
Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
Dana-Farber Cancer Institute -led research helped drive an FDA label update for axicabtagene ciloleucel (Y . . .